April 24, 2023 10:03 AM EDT
R&D
Cell/Gene Tx
FDA+

On Ver­tex and CRISPR Ther­a­peu­tics’ heels, blue­bird sub­mits sick­le cell gene ther­a­py to FDA

Lei Lei Wu

News Reporter

Blue­bird bio said Mon­day morn­ing it has sub­mit­ted an ap­pli­ca­tion for its sick­le cell ther­a­py to the FDA for po­ten­tial ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times